Lu X Y, Tang J, Zhang Z, Ding K
State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, No. 190, Kaiyuan Avenue, Science Park, Guangzhou, 510530, People's Republic of China.
Curr Med Chem. 2015;22(5):651-67. doi: 10.2174/0929867322666141212115236.
In bacterial type II fatty acid biosynthesis (FAS-II), β-ketoacyl-acyl carrier protein (ACP) synthase III (FabH) initiates the first condensation of acyl-CoA and malonyl-ACP to form acetoacetyl-ACP. Its key role for organism survival and specificity to bacteria make it as an essential target for the discovery of novel antibacterial agents. Over the last decade, several structures of FabH from diverse microorganisms have been solved, giving detailed information about the three-dimensional features of the catalytic pocket. This has facilitated the rational design of FabH inhibitors, which provides a framework for future development of antibiotics against multi-drug resistant strains. This review covers recent advances in the biochemical and structural research of FabH and updates the main families of related inhibitors.
在细菌II型脂肪酸生物合成(FAS-II)中,β-酮酰基-酰基载体蛋白(ACP)合酶III(FabH)启动酰基辅酶A和丙二酰-ACP的首次缩合反应,以形成乙酰乙酰-ACP。它对生物体生存的关键作用以及对细菌的特异性使其成为发现新型抗菌剂的重要靶点。在过去十年中,已解析了来自多种微生物的FabH的几种结构,提供了有关催化口袋三维特征的详细信息。这促进了FabH抑制剂的合理设计,为未来开发针对多重耐药菌株的抗生素提供了框架。本综述涵盖了FabH生化和结构研究的最新进展,并更新了相关抑制剂的主要类别。